| Status: Medicine does not meet criteria for AWMSG assessment | |
Denosumab was considered not suitable for AWMSG assessment by the AWMSG Scrutiny Panel at their meeting on 04/06/2026. |
|
Medicine details |
|
| Medicine name | denosumab (Xgeva®) |
| Formulation | 120 mg solution for injection |
| Reference number | 1351 |
| Indication | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma. |
| Company | Amgen Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Scrutiny Panel meeting date | 04/06/2026 |
| Date of issue | 10/06/2026 |